StockData

Lyell Immunopharma vs NeOnc Technologies

LYEL and NTHI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LYEL and NTHI compare

Lyell Immunopharma is the larger company, worth 3.0 times as much as NeOnc Technologies ($335M against $112M).

Lyell Immunopharma scores higher on the StockData Score (6 against 0 for NeOnc Technologies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLYELNTHI
Size and price
Market cap$335M$112M
Share price$13.67$4.33
Change, 1 year−19.3%−52.3%
Change, 5 years−92.7%–
Beta (5Y)1.372.81
Employees–5
StockData Score
Total score6 (better)0
Valuation score1 (better)0
Growth score00
Performance score00
Health score5 (better)0
Dividend score00
Valuation
P/S12407×–
P/B1.4×–
FCF yield−40.0%–
Growth
Revenue growth (TTM)−55.0%–
Revenue growth, 5Y average−65.9%–
Profitability
Operating margin−949981%–
Net margin−920285%–
FCF margin−496189%–
Return on equity−93.3%–
Return on invested capital−782%–
Financial health
Debt / equity0.00–
Interest coverage–−15.7×
Current ratio5.36 (better)0.38
Altman Z-score−7.05 (better)−34.30
Piotroski F-score22
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions48.9%12.2%
Held by insiders45.0%60.1%
Insider net buying, 12 months$74.4M (better)$2.0M
Short interest, % of float10.5%8.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.